Sage Therapeutics Inc (SAGE) - Total Liabilities
Based on the latest financial reports, Sage Therapeutics Inc (SAGE) has total liabilities worth $54.19 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Sage Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Sage Therapeutics Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Sage Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Sage Therapeutics Inc total assets.
Sage Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Sage Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Yida Chemical Co Ltd Class A
SHE:300721
|
China | CN¥1.48 Billion |
|
Hangzhou Chinastars Reflective Material Co.Ltd.
SHE:301077
|
China | CN¥682.93 Million |
|
Chularat Hospital Public Company Limited
BK:CHG
|
Thailand | ฿1.97 Billion |
|
Yantai Longyuan Power Tech
SHE:300105
|
China | CN¥806.00 Million |
|
VRL Logistics Limited
NSE:VRLLOG
|
India | Rs-11.42 Billion |
|
Shenzhen Silver Basis Technology Co Ltd
SHE:002786
|
China | CN¥3.38 Billion |
|
Xiamen Sunrise Wheel Group Co Ltd
SHE:002593
|
China | CN¥2.48 Billion |
|
Brightspire Capital Inc
NYSE:BRSP
|
USA | $2.74 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Sage Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See SAGE equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sage Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sage Therapeutics Inc (2012–2024)
The table below shows the annual total liabilities of Sage Therapeutics Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $82.13 Million | -0.74% |
| 2023-12-31 | $82.75 Million | -20.32% |
| 2022-12-31 | $103.85 Million | +7.89% |
| 2021-12-31 | $96.26 Million | +10.75% |
| 2020-12-31 | $86.91 Million | -37.70% |
| 2019-12-31 | $139.50 Million | +55.45% |
| 2018-12-31 | $89.73 Million | +64.76% |
| 2017-12-31 | $54.46 Million | +51.22% |
| 2016-12-31 | $36.01 Million | +135.06% |
| 2015-12-31 | $15.32 Million | +96.93% |
| 2014-12-31 | $7.78 Million | -80.58% |
| 2013-12-31 | $40.07 Million | +144.48% |
| 2012-12-31 | $16.39 Million | -- |
About Sage Therapeutics Inc
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric m… Read more